BCRX as reported
BioCryst Pharmaceuticals, Inc. reported $941M of revenue over the trailing twelve months, +69% on the year before. 10 reported series are charted on this page, each one as filed.
$941M
Revenue, trailing twelve months · to Q2 2026 · +69% against the twelve months before
- Net Income
- −$385M
Net Income · +977% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $373M
Free Cash Flow · +2269% year on year · trailing twelve months to Q2 2026
- Op Margin
- −80%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $941M | +69% | Q2 2026 |
| Net Income | −$385M | +977% | Q2 2026 |
| EPS | −$1.49 | +728% | Q2 2026 |
| Gross Margin | 98% | n/a | Q2 2026 |
| Op Margin | −80% | n/a | Q2 2026 |
| Net Margin | −89% | n/a | Q2 2026 |
| ROE | −13% | n/a | Q2 2026 |
| ROA | −30% | n/a | Q2 2026 |
| ROIC | 13% | n/a | Q2 2026 |
| Free Cash Flow | $373M | +2269% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
BioCryst Pharmaceuticals, Inc. (BCRX) - Revenue & ProfitRevenue & ProfitBioCryst Pharmaceuticals, Inc. (BCRX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #2 of 28 by Smart Score